OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer May 08, 2018 7:30am EDT
OncoSec Announces PISCES/KEYNOTE-695 Trial-in-Progress Poster Presentation at Upcoming ASCO 2018 Annual Meeting Apr 26, 2018 8:00am EDT
OncoSec Provides Highlights from Research Reception at AACR Annual Meeting 2018 Apr 16, 2018 8:35am EDT
OncoSec to Host Research Reception During the 2018 American Association of Cancer Research Annual Meeting Apr 03, 2018 8:00am EDT
OncoSec's Intratumoral IL-12 In Metastatic Triple Negative Breast Cancer (TNBC) Selected For Oral Poster Presentation At The American Association For Cancer Research (AACR) Annual Meeting 2018 Mar 15, 2018 8:00am EDT
OncoSec Announces Publication In Nature Gene Therapy Demonstrating Efficacy Of IL-12 Intratumoral Gene Electrotransfer Mar 12, 2018 8:00am EDT
OncoSec Medical Incorporated Announces Closing of $23.0 Million Public Offering of Common Stock Feb 06, 2018 8:30am EST
